Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB – Is one NUC better than the other?

Antiviral therapy with oral nucleos(t)ide analogues (NUCs) is recommended by international guidelines for patients with chronic hepatitis B (CHB) who have treatment indications,1 –3 as NUCs are effective in suppressing HBV DNA and reducing the risk of hepatic events and hepatocellular carcinoma (HCC).4,5 Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the 3 recommended NUCs, with high genetic barriers to resistance as well as favora ble safety profiles.1,3,6
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research